Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Is ANDA Bolus Coming As Higher User Fees Loom?

Executive Summary

Generic submission volume remained steady in August as some wonder whether sponsors will rush to avoid a 144% increase in the ANDA user fee taking effect Oct. 1.

You may also be interested in...



Generic User Fee Hikes Could Disrupt US FDA Drug Pricing Campaign

New GDUFA program fee is high enough that sponsors may withdraw applications to reduce their fee exposure, agency estimates.

ANDA Approvals Break Record, May Set New Normal

FDA's June approval total is highest of GDUFA era, but does it signal a new elevated productivity level for the generics program?

Generic Drugs: First-Cycle Review Times Improve, But Hundreds Of ANDAs Still Pending

US FDA cut first-cycle review time 46% between fiscal year 2013 and FY 2015, but more than 900 ANDAs still awaited review by end of 2016.

Related Content

Topics

UsernamePublicRestriction

Register

GB002231

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel